Intrinsic value of Exelixis, Inc. (EXEL)

Previous Close$21.52
Intrinsic Value
Upside potential
Previous Close

VALUATION INPUT DATA (original, your and others' valuations)

Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh101.96 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, and other kinases implicated in growth and spread of cancer. It has collaboration and license agreement with Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., Roche, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Daiichi Sankyo Company, Limited, and clinical collaboration with Ipsen. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

show cash flow forecast


Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046


Revenue growth rate, %45.2NaN
Revenue, $1435NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m1148NaN
Operating income, $m287NaN
EBITDA, $m306NaN
Interest expense (income), $mNaN
Earnings before tax, $m294NaN
Tax expense, $m63NaN
Net income, $m231NaN


Cash and short-term investments, $m1467NaN
Total assets, $m2616NaN
Adjusted assets (=assets-cash), $m1149NaN
Average production assets, $m194NaN
Working capital, $m1497NaN
Total debt, $m56NaN
Total liabilities, $m405NaN
Total equity, $m2211NaN
Debt-to-equity ratio0.025NaN
Adjusted equity ratio0.652NaN


Net income, $m231NaN
Depreciation, amort., depletion, $m19NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m401NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-64NaN
Free cash flow, $m465NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m1497
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN